Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria in the setting of three different chemopreventive regimens

Malaria Journal

Volumn 14, Issue 1, 2015, Pages

  Kapisi, James ^a   Bigira, Victor ^a   Clark, Tamara ^b   Kinara, Stephen ^a   Mwangwa, Florence ^a   Achan, Jane ^c   Kamya, Moses ^c   Soremekun, Seyi ^d   Dorsey, Grant ^a  

^a MULAGO HOSPITAL   (Uganda)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Artemether lumefantrine; Chemoprevention; Dihydroartemisinin piperaquine; Malaria; Sulfadoxine pyrimethamine; Trimethoprimsulfamethoxazole

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; COTRIMOXAZOLE; DIHYDROARTEMISININ PLUS PIPERAQUINE; PYRIMETHAMINE PLUS SULFADOXINE; QUININE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DRUG COMBINATION; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE;

ADOLESCENT; ANOREXIA; ARTICLE; BED NET; BODY TEMPERATURE DISORDER; CAREGIVER; CHEMOPROPHYLAXIS; CHILD; CHRONOTHERAPY; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FOLLOW UP; HIGH RISK POPULATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA; MALARIA CONTROL; MALE; PARASITE CLEARANCE; PARASITE TRANSMISSION; PARASITEMIA; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; SINGLE DRUG DOSE; TREATMENT OUTCOME; TREATMENT RESPONSE; UGANDA; VOMITING; ADVERSE EFFECTS; DRUG COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; PATHOLOGY; PRESCHOOL CHILD; PROCEDURES; RECURRENT DISEASE;

ANTIMALARIALS; ARTEMISININS; CHEMOPREVENTION; CHILD, PRESCHOOL; DRUG COMBINATIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ETHANOLAMINES; FEMALE; FLUORENES; HUMANS; INFANT; MALARIA; MALE; RECURRENCE; TREATMENT OUTCOME; UGANDA;

EID: 84924098651     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-015-0583-9     Document Type: Article

References (15)

1. WHO. World Malaria Report 2013. Geneva, Switzerland: World Health Organization; 2013.
2. Bigira V, Kapisi J, Clark TD, Kinara S, Mwangwa F, Muhindo MK, et al. Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial. PLoS Med. 2014;11:e1001689.
3. Kamya MR, Kapisi J, Bigira V, Clark TD, Kinara S, Mwangwa F, et al. Efficacy and safety of three regimens for the prevention of malaria in young HIV-exposed Ugandan children: a randomized controlled trial. AIDS. 2014;28:2701-9.
4. Kilama M, Smith DL, Hutchinson R, Kigozi R, Yeka A, Lavoy G, et al. Estimating the annual entomological inoculation rate for Plasmodium falciparum transmitted by Anopheles gambiae s.l. using three sampling methods in three sites in Uganda. Malar J. 2014;13:111.
5. WHO. Guidelines for the Treatment of Malaria. 2nd ed. Geneva, Switzerland: World Health Organization; 2010.
6. Osterbauer B, Kapisi J, Bigira V, Mwangwa F, Kinara S, Kamya MR, et al. Factors associated with malaria parasitaemia, malnutrition, and anaemia among HIV-exposed and unexposed Ugandan infants: a cross-sectional survey. Malar J. 2012;11:432.
7. Tarning J, Zongo I, Somé FA, Rouamba N, Parikh S, Rosenthal PJ, et al. Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin Pharmacol Ther. 2012;91:497-505.
8. Ogutu B. Artemether and lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa. Expert Opin Pharmacother. 2013;14:643-54.
9. Egunsola O, Oshikoya KA. Comparative safety of artemether-lumefantrine and other artemisinin-based combinations in children: a systematic review. Malar J. 2013;12:385.
10. Tine RCK, Ndour CT, Faye B, Cairns M, Sylla K, Ndiaye M, et al. Feasibility, safety and effectiveness of combining home based malaria management and seasonal malaria chemoprevention in children less than 10 years in Senegal: a cluster-randomised trial. Trans R Soc Trop Med Hyg. 2014;108:13-21.
11. Muhindo MK, Kakuru A, Jagannathan P, Talisuna A, Osilo E, Orukan F, et al. Early parasite clearance following artemisinin-based combination therapy among Ugandan children with uncomplicated Plasmodium falciparum malaria. Malar J. 2014;13:32.
12. Yeka A, Dorsey G, Kamya MR, Talisuna A, Lugemwa M, Rwakimari JB, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS One. 2008;3:e2390.
13. Conrad MD, LeClair N, Arinaitwe E, Wanzira H, Kakuru A, Bigira V, et al. Comparative impacts over 5 years of artemisinin-based combination therapies on Plasmodium falciparum polymorphisms that modulate drug sensitivity in Ugandan children. J Infect Dis. 2014;210:344-53.
14. Katrak S, Gasasira A, Arinaitwe E, Kakuru A, Wanzira H, Bigira V, et al. Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children. Malar J. 2009;8:272.
15. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411-23.